pharmaceutical stirs outrage over hike
Last Updated : GMT 06:41:18
Arab Today, arab today
Arab Today, arab today

for brain tumor drug

Pharmaceutical stirs outrage over hike

Arab Today, arab today

Arab Today, arab today Pharmaceutical stirs outrage over hike

The drug Lomustine from Bristol-Myers Squibb.
Miami - Arab Today

A little known pharmaceutical company in Florida has found itself in the eye of a storm following disclosures it raised the price of an old drug used to fight brain tumors by 1,400 percent, from $50 a pill to more than $700.

NextSource Biotechnology in 2013 bought the license for the drug Lomustine from Bristol-Myers Squibb, which sold a 100 milligram pill of the substance for nearly $50 apiece.

Since then, according to The Wall Street Journal, it raised the price of the same pill to $768, marketing it in the United States under the name Gleostine.

The patent for Lomustine, which also is known as CeeNU or CCNU, has expired but there is no generic equivalent.

It was developed more than 40 years ago as a chemotherapy treatment for glioblastoma, an aggressive brain tumor.

The Wall Street Journal story set off angry reactions among readers, a wave of accusations on social media of "corporate greed" and an open letter from an association of Democratic activists in Miami-Dade county demanding that NextSource be investigated for "gouging and anti-competitive practices."

Local politicians on Thursday gave their backing to the so-called People's Progressive Caucus of Miami-Dade, which is organizing a protest Saturday outside NextSource's office in downtown Miami.

"More than anything, we'd like to get NextSource to roll back some of their prices," William Bryant, the group's spokesman, told AFP. "But we'd also like to try to secure commitments from our current and future Congress people to materially address the issue of out-of-control pharmaceutical prices."

The website Canada Drugs lists the same drug, under the name CeeNU, at $35 for a 100mg pill.

In an editorial in the September edition of The Cancer Letter, three oncologists and pharmacologists from the Duke University Health System in Durham, North Carolina denounced NextSource's practice of arbitrary price increases as "unconscionable."

"This tactic of extreme price increases of life-saving medications is both repulsive and disheartening," they said.

"In the process of prescribing standard-of-care treatments for our patients, we pose them with an impossible dilemma: either face financial hardship to take the medication or choose not to receive potentially life-saving therapy."

- Price gouging denied -

NextSource's lawyer, Joseph DeMaria, contended that allegations made against the company and its CEO Robert DiCrisci were defamatory and that they might sue.

"This argument that my client is this greedy company and greedy person who is trying to gouge is a total falsehood," he said.

He said NextSource, which only sells Lomustine, also produces lower priced doses of the substance averaging $400 a pill.

The raw material used to make Lomustine, a "trade secret" DeMaria would not identify, has risen by 30 percent, he said, and the company also must pay the Food and Drug Administration $2 million a year.

DeMaria said NextSource moreover has a program to provide the drug free to people who lack health insurance. The Duke specialists, however, said the program's "stringent criteria" limited its availability to only a small minority of patients.

Lomustine, which acts to interfere with the DNA of the cancer cells, is typically prescribed in doses of 110 mg/m2 every six weeks.

According to the American Brain Tumor Association, some 700,000 people in the United States suffer from a primary brain or spinal cord tumor.

Glioblastoma, in particular, accounts for 14.9 percent of all primary brain tumors.

 

Source: AFP

arabstoday
arabstoday

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

pharmaceutical stirs outrage over hike pharmaceutical stirs outrage over hike

 



Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

pharmaceutical stirs outrage over hike pharmaceutical stirs outrage over hike

 



Arab Today, arab today
Arab Today, arab today Skincare PR Performance Full Year 2017

GMT 10:35 2018 Monday ,22 January

Skincare PR Performance Full Year 2017
Arab Today, arab today New hunt for flight MH370 gets under way

GMT 02:36 2018 Wednesday ,24 January

New hunt for flight MH370 gets under way
Arab Today, arab today Modern colorful bedroom renovation

GMT 11:23 2017 Thursday ,21 December

Modern colorful bedroom renovation
Arab Today, arab today France sanctions businesses linked

GMT 01:58 2018 Wednesday ,24 January

France sanctions businesses linked
Arab Today, arab today Turkey detains dozens more

GMT 02:09 2018 Wednesday ,24 January

Turkey detains dozens more
Arab Today, arab today The Rake announces editorial updates

GMT 12:19 2018 Tuesday ,16 January

The Rake announces editorial updates
Arab Today, arab today Europe brings on charm and blue skies

GMT 06:12 2018 Tuesday ,23 January

Europe brings on charm and blue skies
Arab Today, arab today For the Variety of Interior Design Styles

GMT 11:14 2017 Tuesday ,19 December

For the Variety of Interior Design Styles
Arab Today, arab today Puigdemont candidate for Catalan president

GMT 05:31 2018 Tuesday ,23 January

Puigdemont candidate for Catalan president
Arab Today, arab today Amazon to open first cashierless shop

GMT 05:52 2018 Tuesday ,23 January

Amazon to open first cashierless shop

GMT 07:22 2017 Thursday ,23 November

Zimbabwe's next leader heads home after Mugabe exit

GMT 07:23 2017 Thursday ,23 November

Zimbabwe's next leader heads home after Mugabe exit

GMT 22:38 2018 Tuesday ,23 January

Bahrain Press headlines

GMT 20:34 2018 Saturday ,20 January

Bahrain press headlines

GMT 16:25 2016 Thursday ,22 December

Italian bank Monte Paschi edges closer to state bailout

GMT 06:03 2014 Wednesday ,09 April

Please .. Let Gaza breathe!

GMT 09:12 2017 Friday ,17 November

Gleam Futures represents Grace Beverley

GMT 04:18 2017 Sunday ,26 November

Bella magazine appoints celebrity writer

GMT 06:00 2017 Sunday ,29 October

Childrenswear brand Once appoints Dyelog

GMT 16:33 2014 Thursday ,13 November

Al-Ehtimam Bil Aakhareen

GMT 03:34 2017 Sunday ,05 November

Needle & Thread relocates press office

GMT 14:56 2017 Thursday ,21 December

Ryanair says formally recognises pilots' union

GMT 01:41 2017 Saturday ,12 August

Moroccan video sparks debate on sexual harassment

GMT 16:03 2017 Thursday ,21 December

US hits Myanmar general in new global rights sanctions

GMT 15:56 2017 Monday ,18 December

EVE LOM to launch Radiance Face Oil

GMT 14:36 2017 Thursday ,21 December

Sixteen dead in sauna fire in S. Korea

GMT 16:08 2017 Tuesday ,24 October

Glamour fashion editor goes freelance

GMT 10:26 2017 Thursday ,21 December

Charlotte Connoley announces blog launch
Arab Today, arab today
Arab Today, arab today
 
 Arab Today Facebook,arab today facebook  Arab Today Twitter,arab today twitter Arab Today Rss,arab today rss  Arab Today Youtube,arab today youtube  Arab Today Youtube,arab today youtube
arabstoday arabstoday arabstoday arabstoday
arabstoday arabstoday arabstoday
arabstoday
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
arabstoday, Arabstoday, Arabstoday